Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma
Brief Summary: Primary Objective:

To evaluate the efficacy of different doses and regimens of dupilumab in participants with moderate to severe uncontrolled asthma.

Secondary Objective:

To evaluate different doses and regimens of dupilumab in participants with moderate to severe uncontrolled asthma, with regard to:

* Safety and tolerability
* Dupilumab systemic exposure and anti-drug antibodies


Options:
A: Arm Label: Benralizumab treatment group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Benralizumab | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Benralizumab; Assigned to Arm(s): Benralizumab treatment group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo group
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Mometasone furoate 50 micrograms | Arm Label: Dupilumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab SAR231893 (REGN668), Drug: Mometasone furoate 50 micrograms | Intervention Type: DRUG; Name: Dupilumab SAR231893 (REGN668); Assigned to Arm(s): Dupilumab 300 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Mometasone furoate 50 micrograms; Assigned to Arm(s): Dupilumab 300 mg, Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-IgE antibody omalizumab or placebo | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Anti-IgE antibody omalizumab or placebo | Intervention Type: DRUG; Name: Anti-IgE antibody omalizumab or placebo; Assigned to Arm(s): 1, 2
D: Arm Label: Dupilumab 300 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: ICS/LABA therapy, Drug: Salbutamol/albuterol, Drug: Levosalbutamol/levalbuterol | Arm Label: Dupilumab 200 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: ICS/LABA therapy, Drug: Salbutamol/albuterol, Drug: Levosalbutamol/levalbuterol | Arm Label: Dupilumab 300 mg q4w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: placebo, Drug: ICS/LABA therapy, Drug: Salbutamol/albuterol, Drug: Levosalbutamol/levalbuterol | Arm Label: Dupilumab 200 mg q4w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: placebo, Drug: ICS/LABA therapy, Drug: Salbutamol/albuterol, Drug: Levosalbutamol/levalbuterol | Arm Label: Placebo q2w; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Drug: ICS/LABA therapy, Drug: Salbutamol/albuterol, Drug: Levosalbutamol/levalbuterol | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 200 mg q4w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Dupilumab 200 mg q4w, Dupilumab 300 mg q4w, Placebo q2w | Intervention Type: DRUG; Name: ICS/LABA therapy; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 200 mg q4w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Placebo q2w | Intervention Type: DRUG; Name: Salbutamol/albuterol; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 200 mg q4w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Placebo q2w | Intervention Type: DRUG; Name: Levosalbutamol/levalbuterol; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 200 mg q4w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Placebo q2w

Answer: D